These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 10707569)
21. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted? Standl E; Schnell O Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474 [No Abstract] [Full Text] [Related]
22. Pharmacological regulation of blood glucose levels in non-insulin-dependent diabetes mellitus. Bressler R; Johnson DG Arch Intern Med; 1997 Apr; 157(8):836-48. PubMed ID: 9129543 [TBL] [Abstract][Full Text] [Related]
23. Effects of thiazolidinediones and sulfonylureas in patients with diabetes. Derosa G; Maffioli P Diabetes Technol Ther; 2010 Jun; 12(6):491-501. PubMed ID: 20470234 [TBL] [Abstract][Full Text] [Related]
24. [Kidney disease and insulin resistance--clinical impact of thiazolidinedione compounds for kidney disease]. Isshiki K; Haneda M; Koya D; Kikkawa R Nihon Rinsho; 2000 Feb; 58(2):440-5. PubMed ID: 10707573 [TBL] [Abstract][Full Text] [Related]
25. [Pioglitazone]. Kobayashi M; Iwata M; Hiratani K Nihon Rinsho; 2002 Sep; 60 Suppl 9():429-37. PubMed ID: 12387029 [No Abstract] [Full Text] [Related]
26. Review of the Case Reports on Metformin, Sulfonylurea, and Thiazolidinedione Therapies in Type 2 Diabetes Mellitus Patients. Susilawati E; Levita J; Susilawati Y; Sumiwi SA Med Sci (Basel); 2023 Aug; 11(3):. PubMed ID: 37606429 [TBL] [Abstract][Full Text] [Related]
27. Pioglitazone and sulfonylureas: effectively treating type 2 diabetes. Hanefeld M Int J Clin Pract Suppl; 2007 Jun; 61(153):20-7. PubMed ID: 17594390 [TBL] [Abstract][Full Text] [Related]
28. Pioglitazone. Lawrence JM; Reckless JP Int J Clin Pract; 2000 Nov; 54(9):614-8. PubMed ID: 11220991 [TBL] [Abstract][Full Text] [Related]
29. Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus. Strowig SM; Raskin P Diabetes Obes Metab; 2005 Nov; 7(6):633-41. PubMed ID: 16219007 [TBL] [Abstract][Full Text] [Related]
30. New directions in type 2 diabetes mellitus: an update of current oral antidiabetic therapy. Brown DL; Brillon D J Natl Med Assoc; 1999 Jul; 91(7):389-95. PubMed ID: 10643211 [TBL] [Abstract][Full Text] [Related]
31. Clinical evaluation of pioglitazone in patients with type 2 diabetes using alpha-glucosidase inhibitor and examination of its efficacy profile. Hayashi Y; Miyachi N; Takeuchi T; Takeuchi Y; Kamiya F; Kato T; Imaeda K; Okayama N; Shimizu M; Itoh M Diabetes Obes Metab; 2003 Jan; 5(1):58-65. PubMed ID: 12542726 [TBL] [Abstract][Full Text] [Related]
32. Thiazolidinediones in diabetes: current status and future outlook. Camp HS Curr Opin Investig Drugs; 2003 Apr; 4(4):406-11. PubMed ID: 12808879 [TBL] [Abstract][Full Text] [Related]
34. Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients. Kumar S; Prange A; Schulze J; Lettis S; Barnett AH Diabet Med; 1998 Sep; 15(9):772-9. PubMed ID: 9737807 [TBL] [Abstract][Full Text] [Related]
35. Oral combination therapy for type 2 diabetes. Charpentier G Diabetes Metab Res Rev; 2002; 18 Suppl 3():S70-6. PubMed ID: 12324989 [TBL] [Abstract][Full Text] [Related]
36. Oral agents in the management of type 2 diabetes mellitus. Luna B; Feinglos MN Am Fam Physician; 2001 May; 63(9):1747-56. PubMed ID: 11352285 [TBL] [Abstract][Full Text] [Related]
37. Effects of troglitazone on insulin sensitivity. Henry RR Diabet Med; 1996 Sep; 13(9 Suppl 6):S148-50. PubMed ID: 8894499 [TBL] [Abstract][Full Text] [Related]
38. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes. Sironi AM; Vichi S; Gastaldelli A; Pecori N; Anichini R; Foot E; Seghieri G; Ferrannini E Clin Pharmacol Ther; 1997 Aug; 62(2):194-202. PubMed ID: 9284856 [TBL] [Abstract][Full Text] [Related]
39. [Mechanisms of thiazolidinedione derivatives for hypoglycemic and insulin sensitizing effects]. Sugiyama Y Nihon Rinsho; 2002 Sep; 60 Suppl 9():416-21. PubMed ID: 12387027 [No Abstract] [Full Text] [Related]
40. Oral combination therapy with thiazolidinediones in type 2 diabetes. LaSalle JR; Cross LB Am J Manag Care; 2006 Nov; 12(14 Suppl):S369-81. PubMed ID: 17112324 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]